Skip to main content
. 2020 Feb 4;15(1):39–47. doi: 10.1016/j.jtumed.2019.12.005

Table 6.

Relative resistance of isolated organisms to relevant antibiotics.

Antibiotics tested Gram-negative
Gram-positive
Klebsiella
Pseudomonas
Enterobacter
Acinetobacter
CoNS
MRSA
Strept.
R/T (%) R/T (%) R/T (%) R/T (%) R/T (%) R/T (%) R/T (%)
Polymyxin 0/4(0) 0/8(0)
Gentamycin 32/34(94) 4/4(100) 3/3(100) 6/8(75) 13/14(93) 7/7(100) 1/1(100)
Amikacin 28/34(82) 1/2 (50) 1/3(33) 6/8(75)
Meropenem 32/34(94) 1/1(100) 3/3(100) 1/1(100)
Imipenem 31/34(91) 4/4(100) 3/3(100) 8/8(100)
Ciprofloxacin 28/34(82) 4/4(100) 1/3(33) 6/8(75) 13/13(100) 7/7(100) 2/2(100)
Levofloxacin 16/34(47) 4/4(100) 0/3(0) 6/8(75) 13/14(93) 7/7(100) 2/2(100)
SXT 29/34(85) IR 3/3(100) 7/8(88) 13/14(93) 7/7(100)
Ampicillin-sulbactam 34/34(100) IR 3/3(100) 8/8(100) 17/17(100) 7/7(100) 2/2(100)
Amoxiclav 34/34(100) IR 3/3(100) 8/8(100) 15/15(100) 7/7(100) 1/1(100)
Pip-tazo 34/34(100) 1/2(50) 3/3(100) 8/8(100)
Sulperazone 34/34(100) 1/1(100) 3/3(100) 8/8(100)
Ceftazidime 34/34(100) 3/3(100) 8/8(100)
Cefotaxime 34/34(100) IR 3/3(100) 8/8(100) 14/15(93) 7/7(100) 0/1(0)
Ceftriaxone 34/34(100) IR 3/3(100) 8/8(100) 14/14(100) 7/7(100)
Cefuroxime 34/34(100) IR 3/3(100) IR 14/14(100)
Cefoperazone 34/34(100) IR 3/3(100) 8/8(100) 14/14(100) 7/7(100)
Cefepime 34/34(100) 3/3(100) 3/3(100) 8/8(100) 14/14(100)
Cefoxitin 34/34(100) 1/2(50) 3/3(100) 8/8(100) 14/14(100) 7/7(100)
Rifampicin 13/17(76) 5/6(83)
Vancomycin 0/17(0) 0/7(0) 1/2(50)
Chloramphenicol 13/17(76) 2/7(29)
Linezolid 0/6(0) 0/3(0) 2/2(100)
Clindamycin 12/17(71) 2/7(29) 0/1(0)
Erythromycin 15/17(88) 7/7(100) 0/1(0)

R/T: Number of resistant organisms/total; IR: intrinsic resistance; CoNS: coagulase-negative staphylococci; MRSA: methicillin-resistant Staphylococcus aureus; strept: streptococci; amociclav: amoxicillin-clavulanic acid; pip-tazo: piperacillin tazobactam; SXT: sulfamethoxazole trimethoprim.

Data are presented as numbers (percentages).